NCT06375811
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
Active, Not Recruiting
PHASE3Ages 18–40InterventionalTreatmentYale UniversityInvestigator-initiated
~97 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Elagolix 200 MGPlacebo or SOC IVF
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Live birth rate
Measured over Up to 15 months
Conditions
Where it's being run
5 sites across 5 statesColorado1
Connecticut1
Illinois1
Maryland1
North Carolina1
Study leadership
- Hugh Taylor, MD · PRINCIPAL_INVESTIGATOR · Yale University
- Heping Zhang, PhD · STUDY_DIRECTOR · Yale University
- Nanette Santoro, MD · STUDY_DIRECTOR · University of Colorado, Denver
- Emily Jungheim, MD · STUDY_DIRECTOR · Northwestern University
- Steven Young, MD, PhD · STUDY_DIRECTOR · Duke University
- Jim Segars, MD · STUDY_DIRECTOR · Johns Hopkins University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Live birth rateUp to 15 months
Live birth rate per participant is defined as live birth at ≥24 weeks of gestation.